Molecular Targets for Breast Cancer Therapy, 2nd Edition

Dear Colleagues,

Following a very successful first edition, we are pleased to announce the launch of the second edition of this Special Issue, entitled “Molecular Targets for Breast Cancer Therapy, 2nd Edition”.

After the cytotoxic chemotherapy era, marked by severe toxicities and multi-drug resistance, “molecularly targeted drugs” have brought new hope in the battle against cancer. However, despite the occasional introduction of new drugs, resistance seems to be inevitable. A sub-population of the tumor cells often fails to respond favorably to the initial treatment (likely due to tumor cell heterogeneity causing intrinsic resistance). This “Darwinian clone selection” is documented in different types of cancer in response to a variety of molecularly targeted drugs. On the other hand, initially responsive cells become resistant shortly after repeated doses (acquired resistance), which, in addition to point mutations, could be due to the plasticity of cancer cells that have access to a variety of signaling pathways that can compensate for the targeted protein. Therefore, the identification of new targets is crucial to overcoming these obstacles. This Special Issue focuses on breast cancer and sheds light on the most recent efforts in the identification of novel molecular targets or the newly discovered crosstalk among the established signaling pathways. Our goal is to create a platform to present information about the molecular mechanism(s) involved in proliferation, survival, and/or resistance in breast cancer cells that can lead to new treatment strategies.

Dr. Hamidreza Montazeri Aliabadi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• breast cancer
• molecular targets
• signaling pathways
• proliferation
• survival
• resistance
• crosstalk

• Molecular Targets for Breast Cancer Therapy in Biomolecules (5 articles)